- Home
- RERE vs TLRY Comparison
RERE vs TLRY Comparison
Compare RERE & TLRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RERE | TLRY |
|---|---|---|
| Founded | 2011 | N/A |
| Country | China | Canada |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 859.3M | 919.2M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | RERE | TLRY |
|---|---|---|
| Price | $4.77 | $6.30 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $103.33 |
| AVG Volume (30 Days) | 1.4M | ★ 2.2M |
| Earning Date | 03-11-2026 | 04-01-2026 |
| Dividend Yield | ★ 2.03% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $26.81 | $7.39 |
| Revenue Next Year | $22.92 | $7.17 |
| P/E Ratio | $34.57 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.00 | $0.36 |
| 52 Week High | $6.47 | $15.70 |
Technical Indicators
Market Signals| Indicator | RERE | TLRY |
|---|---|---|
| Relative Strength Index (RSI) | 37.25 | 36.31 |
| Support Level | $3.78 | $1.00 |
| Resistance Level | $4.89 | $8.20 |
| Average True Range (ATR) | 0.26 | 0.32 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 1.66 | 13.04 |
Price Performance
Historical ComparisonAbout RERE ATRenew Inc.
ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platform. The Company's principal operations and geographic markets are in the People's Republic of China.
About TLRY Tilray Brands Inc.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure comes mainly from alcohol.